scholarly journals Development and Validation of a Novel Prognostic Score Based on Thrombotic and Inflammatory Biomarkers for Predicting 28-Day Adverse Outcomes in Patients with Acute Pancreatitis

2022 ◽  
Vol Volume 15 ◽  
pp. 395-408
Author(s):  
Tianyong Han ◽  
Tao Cheng ◽  
Ye Liao ◽  
Yarong He ◽  
Bofu Liu ◽  
...  
2021 ◽  
Vol 9 (3) ◽  
pp. e002277 ◽  
Author(s):  
Gino M Dettorre ◽  
Saoirse Dolly ◽  
Angela Loizidou ◽  
John Chester ◽  
Amanda Jackson ◽  
...  

BackgroundPatients with cancer are particularly susceptible to SARS-CoV-2 infection. The systemic inflammatory response is a pathogenic mechanism shared by cancer progression and COVID-19. We investigated systemic inflammation as a driver of severity and mortality from COVID-19, evaluating the prognostic role of commonly used inflammatory indices in SARS-CoV-2-infected patients with cancer accrued to the OnCovid study.MethodsIn a multicenter cohort of SARS-CoV-2-infected patients with cancer in Europe, we evaluated dynamic changes in neutrophil:lymphocyte ratio (NLR); platelet:lymphocyte ratio (PLR); Prognostic Nutritional Index (PNI), renamed the OnCovid Inflammatory Score (OIS); modified Glasgow Prognostic Score (mGPS); and Prognostic Index (PI) in relation to oncological and COVID-19 infection features, testing their prognostic potential in independent training (n=529) and validation (n=542) sets.ResultsWe evaluated 1071 eligible patients, of which 625 (58.3%) were men, and 420 were patients with malignancy in advanced stage (39.2%), most commonly genitourinary (n=216, 20.2%). 844 (78.8%) had ≥1 comorbidity and 754 (70.4%) had ≥1 COVID-19 complication. NLR, OIS, and mGPS worsened at COVID-19 diagnosis compared with pre-COVID-19 measurement (p<0.01), recovering in survivors to pre-COVID-19 levels. Patients in poorer risk categories for each index except the PLR exhibited higher mortality rates (p<0.001) and shorter median overall survival in the training and validation sets (p<0.01). Multivariable analyses revealed the OIS to be most independently predictive of survival (validation set HR 2.48, 95% CI 1.47 to 4.20, p=0.001; adjusted concordance index score 0.611).ConclusionsSystemic inflammation is a validated prognostic domain in SARS-CoV-2-infected patients with cancer and can be used as a bedside predictor of adverse outcome. Lymphocytopenia and hypoalbuminemia as computed by the OIS are independently predictive of severe COVID-19, supporting their use for risk stratification. Reversal of the COVID-19-induced proinflammatory state is a putative therapeutic strategy in patients with cancer.


Author(s):  
Maaike Biewenga ◽  
Xavier P.D.M.J. Verhelst ◽  
Martine A.M.C. Baven‐Pronk ◽  
Hein Putter ◽  
Aad P. Berg ◽  
...  

Pancreatology ◽  
2021 ◽  
Author(s):  
Awais Ahmed ◽  
Jason C. Fisher ◽  
Mark B. Pochapin ◽  
Steven D. Freedman ◽  
Darshan J. Kothari ◽  
...  

2019 ◽  
Vol 33 (2) ◽  
pp. 499-507 ◽  
Author(s):  
Virginie Fabrès ◽  
Olivier Dossin ◽  
Clémence Reif ◽  
Miguel Campos ◽  
Valerie Freiche ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Chansik An ◽  
Hyun Cheol Oh ◽  
Jung Hyun Chang ◽  
Seung-Jin Oh ◽  
Jung Mo Lee ◽  
...  

AbstractWe developed a tool to guide decision-making for early triage of COVID-19 patients based on a predicted prognosis, using a Korean national cohort of 5,596 patients, and validated the developed tool with an external cohort of 445 patients treated in a single institution. Predictors chosen for our model were older age, male sex, subjective fever, dyspnea, altered consciousness, temperature ≥ 37.5 °C, heart rate ≥ 100 bpm, systolic blood pressure ≥ 160 mmHg, diabetes mellitus, heart disease, chronic kidney disease, cancer, dementia, anemia, leukocytosis, lymphocytopenia, and thrombocytopenia. In the external validation, when age, sex, symptoms, and underlying disease were used as predictors, the AUC used as an evaluation metric for our model’s performance was 0.850 in predicting whether a patient will require at least oxygen therapy and 0.833 in predicting whether a patient will need critical care or die from COVID-19. The AUCs improved to 0.871 and 0.864, respectively, when additional information on vital signs and blood test results were also used. In contrast, the protocols currently recommended in Korea showed AUCs less than 0.75. An application for calculating the prognostic score in COVID-19 patients based on the results of this study is presented on our website (https://nhimc.shinyapps.io/ih-psc/), where the results of the validation ongoing in our institution are periodically updated.


2019 ◽  
Vol Volume 11 ◽  
pp. 5187-5195 ◽  
Author(s):  
Meng-Xin Tian ◽  
Liu-Ping Luo ◽  
Wei-Ren Liu ◽  
Wei Deng ◽  
Jia-Cheng Yin ◽  
...  

2019 ◽  
Vol 114 (5) ◽  
pp. 764-770 ◽  
Author(s):  
Christian Labenz ◽  
Gerrit Toenges ◽  
Yvonne Huber ◽  
Michael Nagel ◽  
Jens U. Marquardt ◽  
...  

2015 ◽  
Vol 110 ◽  
pp. S14
Author(s):  
Ben Da ◽  
Michael Quezada ◽  
Ira Shulman ◽  
Sarah Sheibani ◽  
James L. Buxbaum

Sign in / Sign up

Export Citation Format

Share Document